SB 11285 is a second generation STING agonist that is administered intravenously and has promising uptake into immune cells. Preclinical studies indicate potential advantages over first generation intratumorally-delivered STING agonists.
Activation of the STING (Stimulator of Interferon Genes) pathway induces both innate and adaptive immunity and subsequent activation of cytotoxic T cells and NK cells.
Our Phase 1/2 trial is ongoing, both as monotherapy and in combination with atezolizumab.
